Teva Pharmaceutical Industries has secured approval for generic Tribenzor (olmesartan medoxomil, amlodipine and hydrochlorothiazide) tablets in the US and is in the last stages of launch preparation.

The firm also recently secured approval and launched generic Azor (amlodipine and olmesartan medoxomil) tablets in the US.

These products expand Teva’s anti-hypertensive portfolio.

Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are a combination of an angiotensin II receptor blocker, a dihydropyridine calcium channel blocker and a thiazide diuretic meant to treat hypertension and lower blood pressure.

"Teva stated that it is committed to bolstering its generics business through continued investment in complex, high-quality products."

Amlodipine and olmesartan medoxomil tablets are a dihydropyridine calcium channel blocker and angiotensin II receptor blocker combination product meant for the treatment of hypertension, either alone or with other antihypertensive agents to reduce blood pressure.

Reducing blood pressure cuts down the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Several patients will need more than one drug to meet their blood pressure goals.

Teva stated that it is committed to bolstering its generics business through continued investment in complex, high-quality products.

With nearly 600 generic medicines available, the firm has the largest portfolio of FDA-approved generic products on the market.

It also has more than 300 product registrations pending FDA approval and holds a leading position in first-to-file opportunities, with more than 100 pending first-to-files in the US.

One in six generic prescriptions currently dispensed in the US is filled with a Teva generic product, the company claimed.